Synthetic Cannabinoids as drugs of abuse

Current Drug Abuse Reviews

Volumn 5, Issue 2, 2012, Pages 158-168

  Ashton, John C ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Aminoalkylindole; Bicyclic; Cannabinoid; Cannabinoid receptor; Cannabis; CB1 receptor; CP47,497; HU210; JWH018; K2; Spice; Toxicity; Tricyclic

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABIS; DRONABINOL; ENDOCANNABINOID; LEVONANTRADOL; PSYCHOTROPIC AGENT; SEROTONIN RECEPTOR;

ADRENERGIC SYSTEM; ANXIETY; ATAXIA; BINDING AFFINITY; BIOCHEMISTRY; BIOLOGICAL ACTIVITY; CARDIOVASCULAR DISEASE; CHEMICAL STRUCTURE; DISEASE EXACERBATION; DIZZINESS; DROWSINESS; DRUG ABUSE; DRUG CLASSIFICATION; DRUG IDENTIFICATION; DRUG LEGISLATION; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG WITHDRAWAL; EUPHORIA; FORENSIC IDENTIFICATION; HUMAN; MOOD DISORDER; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TARGETING; PSYCHOSIS; RECEPTOR BINDING; REVIEW; RISK BENEFIT ANALYSIS; SEIZURE; SIDE EFFECT; SOMNOLENCE;

EID: 84861156461     PISSN: 18744737     EISSN: 18744745     Source Type: Journal    
DOI: 10.2174/1874473711205020158     Document Type: Review

References (116)

1. Frankhauser M. History of Cannabis in Western Medicine. In: Grotenhermen F, Russo E, Eds. Cannabis and Cannabinoids: Pharmacology, Toxicology, and Therapeutic Potential. New York: The Haworth Integrative Healing Press 2002.
2. Mechoulam R, Gaoni Y. A total synthesis of Dl-Delta-1-tetrahydrocannabinol, the active constituent of hashish. J Am Chem Soc 1965; 87: 3273-3275.
3. Auwarter V, Dresen S, Weinmann W, Muller M, Putz M, Ferreiros N. 'Spice' and other herbal blends: harmless incense or cannabinoid designer drugs? J Mass Spectrom 2009; 44(5): 832-837.
4. Fattore L, Fratta W. Beyond THC: The New Generation of Cannabinoid Designer Drugs. Front Behav Neurosci 2011; 5: 60.
5. Wells DL, Ott CA. The new marijuana. Ann Pharmacother 2011; 45(3): 414-417.
6. Hudson S, Ramsey J. The emergence and analysis of synthetic cannabinoids. Drug Test Anal 2011; 3(7/8): 466-478.
7. Lindigkeit R, Boehme A, Eiserloh I, et al. Spice: a never ending story? Forensic Sci Int 2009; 191(1/3): 58-63.
8. DEA. Spice - plant material(s) laced with synthetic cannabinoids or cannabinoid mimicking compounds. In: Justice. UDo, editor.: DEA Microgram Bulletin 2009; pp. 73-76.
9. Rosenbaum CD, Carreiro SP, Babu KM. Here Today, Gone Tomorrow...and Back Again? A Review of Herbal Marijuana Alternatives (K2, Spice), Synthetic Cathinones (Bath Salts), Kratom, Salvia divinorum, Methoxetamine, and Piperazines. J Med Toxicol 2012; 8(1): 15-32.
10. Seely KA, Prather PL, James LP, Moran JH. Marijuana-based drugs: innovative therapeutics or designer drugs of abuse? Mol Interv 2011; 11(1): 36-51.
11. Schep LJ, Slaughter RJ, Temple WA, Nair SM, Gee PA. Synthetic cannabinoid analogues--not repeating past mistakes. N Z Med J 2011; 124(1332): 85-86.
12. Kidson S. Doctor slams synthetic cannabis. Nelson Mail 2011, 18 Jun 2011.
13. Hu X, Primack BA, Barnett TE, Cook RL. College students and use of K2: an emerging drug of abuse in young persons. Subst Abuse Treat Prev Policy 2011; 6: 16.
14. Steup C. Untersuchung des Handelsproduktes "Spice". THC Pharm GmbH 2008.
15. EMCDDA. Understanding the Spice phenomenon. Action on new drugs briefing paper 2009.
16. Dresen S, Ferreiros N, Putz M, Westphal F, Zimmermann R, Auwarter V. Monitoring of herbal mixtures potentially containing synthetic cannabinoids as psychoactive compounds. J Mass Spectrom 2010; 45(10): 1186-1194.
17. Vardakou I, Pistos C, Spiliopoulou C. Spice drugs as a new trend: mode of action, identification and legislation. Toxicol Lett 2010; 197(3): 157-162.
18. Atwood BK, Huffman J, Straiker A, Mackie K. JWH018, a common constituent of 'Spice' herbal blends, is a potent and efficacious cannabinoid CB receptor agonist. Br J Pharmacol 2010; 160(3): 585-593.
19. Atwood BK, Lee D, Straiker A, Widlanski TS, Mackie K. CP47,497-C8 and JWH073, commonly found in 'Spice' herbal blends, are potent and efficacious CB(1) cannabinoid receptor agonists. Eur J Pharmacol 2011; 659(2/3): 139-145.
20. Ernst L, Schiebel HM, Theuring C, Lindigkeit R, Beuerle T. Identification and characterization of JWH-122 used as new ingredient in Spice-like herbal incenses. Forensic Sci Int 2011; 208(1/3): e31-e35.
21. Dargan PI, Hudson S, Ramsey J, Wood DM. The impact of changes in UK classification of the synthetic cannabinoid receptor agonists in 'Spice'. Int J Drug Policy 2011; 22(4): 274-277.
22. Porteous D. Ban on Tai High 'legal highs'. Otago Daily Times. 2011 22 Dec 2011.
23. Dresen S, Kneisel S, Weinmann W, Zimmermann R, Auwarter V. Development and validation of a liquid chromatography-tandem mass spectrometry method for the quantitation of synthetic cannabinoids of the aminoalkylindole type and methanandamide in serum and its application to forensic samples. J Mass Spectrom 2011; 46(2): 163-171.
24. Hermanns-Clausen M, Kneisel S, Auwaerter V. New Drugs of Abuse: Acute Intoxication by Smoking Herbal Products Containing Synthetic Cannabinoids. Clin Toxicol 2011; 49(3): 199.
25. Sedefov R, Gallegos A. The European Early Warning System: Responding to Novel and Emerging Recreational Drugs. Clin Toxicol 2011; 49(3): 200.
26. Hutter M, Broecker S, Kneisel S, Auwarter V. Identification of the major urinary metabolites in man of seven synthetic cannabinoids of the aminoalkylindole type present as adulterants in 'herbal mixtures' using LC-MS/MS techniques. J Mass Spectrom 2012; 47(1): 54-65.
27. Ashton JC, Wright JL, McPartland JM, Tyndall JD. Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective agonists. Curr Med Chem 2008; 15(14): 1428-1443.
28. Rinaldi-Carmona M, Pialot F, et al. Characterization and distribution of binding sites for [3H]-SR 141716A, a selective brain (CB1) cannabinoid receptor antagonist, in rodent brain. Life Sci 1996; 58(15): 1239-1247.
29. Jain AK, Ryan JR, McMahon FG, Smith G. Evaluation of intramuscular levonantradol and placebo in acute postoperative pain. J Clin Pharmacol 1981; 21: 320S-326S.
30. Kuster JE, Stevenson JI, Ward SJ, D'Ambra TE, Haycock DA. Aminoalkylindole binding in rat cerebellum: selective displacement by natural and synthetic cannabinoids. J Pharmacol Exp Ther 1993; 264(3): 1352-1363.
31. Porter AC, Sauer JM, Knierman MD, et al. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther 2002; 301(3): 1020-1024.
32. Rinaldi-Carmona M, Barth F, Heaulme M, et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 1994; 350(2/3): 240-244.
33. Atwood BK, Mackie K. CB2: a cannabinoid receptor with an identity crisis. Br J Pharmacol 2010; 160(3): 467-479.
34. Elphick MR, Egertova M. The neurobiology and evolution of cannabinoid signalling. Philos Trans R Soc Lond B Biol Sci 2001; 356(1407): 381-408.
35. Devane WA, Dysarz FA, 3rd, Johnson MR, Melvin LS, Howlett AC. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988; 34(5): 605-613.
36. Herkenham M, Lynn AB, Little MD, et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A 1990; 87(5): 1932-1936.
37. Hu B, Doods H, Treede RD, Ceci A. Depression-like behaviour in rats with mononeuropathy is reduced by the CB2-selective agonist GW405833. Pain 2009; 143(3): 206-212.
38. Izzo AA, Mascolo N, Capasso F. The gastrointestinal pharmacology of cannabinoids. Curr Opin Pharmacol 2001; 1(6): 597-603.
39. Njie YF, Kumar A, Qiao Z, Zhong L, Song ZH. Noladin ether acts on trabecular meshwork cannabinoid (CB1) receptors to enhance aqueous humor outflow facility. Invest Ophthalmol Vis Sci 2006; 47(5): 1999-2005.
40. Park B, Gibbons HM, Mitchell MD, Glass M. Identification of the CB1 cannabinoid receptor and fatty acid amide hydrolase (FAAH) in the human placenta. Placenta 2003; 24(10): 990-995.
41. di Marzo V. A brief history of cannabinoid and endocannabinoid pharmacology as inspired by the work of British scientists. Trends Pharmacol Sci 2006; 27(3): 134-140.
42. Scotter E, Graham S, Glass M. Cannabinoid Receptor Signal Transduction Pathways. In: Reggio P, Ed. Cannabinoids: Structure and Function: Humana Press 2006.
43. van der Stelt M, Di Marzo V. Anandamide as an intracellular messenger regulating ion channel activity. Prostaglandins Lipid Mediat 2005; 77(1/4): 111-122.
44. (BCHD10-115). Public Health Advisory - evolving new drug abuse problem - synthetic marijuana. In: NJLINCS-HAN, Ed. Burlington County 2010.
45. Jones N. Kronic sedative can put users in coma. New Zealand Herald. 2011 1 July 2011.
46. Elphick MR, Egertova M. The neurobiology and evolution of cannabinoid signalling. Philos Trans R Soc Lond 2001; 356(1407): 381-408.
47. Marsicano G, Goodenough S, Monory K, et al. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science (New York, NY) 2003; 302(5642): 84-88.
48. Domenici MR, Azad SC, Marsicano G, et al. Cannabinoid receptor type 1 located on presynaptic terminals of principal neurons in the forebrain controls glutamatergic synaptic transmission. J Neurosci 2006; 26(21): 5794-5799.
49. Hoffman AF, Riegel AC, Lupica CR. Functional localization of cannabinoid receptors and endogenous cannabinoid production in distinct neuron populations of the hippocampus. Eur J Neurosci 2003; 18(3): 524-534.
50. Herkenham M, Lynn AB, Little MD, et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A 1990; 87(5): 1932-1936.
51. Mailleux P, Vanderhaeghen JJ. Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry. Neuroscience 1992; 48(3): 655-668.
52. Williams CM, Rogers PJ, Kirkham TC. Hyperphagia in pre-fed rats following oral delta9-THC. Physiol Behav 1998; 65(2): 343-346.
53. Iversen L. The Science of Marijuana. Oxford: Oxford University Press 2000.
54. Wagner JA, Hu K, Bauersachs J, et al. Endogenous cannabinoids mediate hypotension after experimental myocardial infarction. J Am Coll Cardiol 2001; 38(7): 2048-2054.
55. Bilfinger TV, Salzet M, Fimiani C, Deutsch DG, Tramu G, Stefano GB. Pharmacological evidence for anandamide amidase in human cardiac and vascular tissues. Int J Cardiol 1998; 64(Suppl 1): S15-S22.
56. Niederhoffer N, Schmid K, Szabo B. The peripheral sympathetic nervous system is the major target of cannabinoids in eliciting cardiovascular depression. Naunyn Schmiedebergs Arch Pharmacol 2003; 367(5): 434-443.
57. Szabo B, Nordheim U, Niederhoffer N. Effects of cannabinoids on sympathetic and parasympathetic neuroeffector transmission in the rabbit heart. J Pharmacol Exp Ther 2001; 297(2): 819-826.
58. Kunos G, Batkai S, Offertaler L, et al. The quest for a vascular endothelial cannabinoid receptor. Chem Phys Lipids 2002; 121(1/2): 45-56.
59. Kronstrand R, Roman M, Thelander G, Eriksson A. Unintentional fatal intoxications with mitragynine and O-desmethyltramadol from the herbal blend Krypton. J Anal Toxicol 2011; 35(4): 242-247.
60. Iversen L. Cannabis and the brain. Brain 2003; 126(Pt 6): 1252-1270.
61. Berman JS, Symonds C, Birch R. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain 2004; 112(3): 299-306.
62. Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005; 65(6): 812-819.
63. Cronin CM, Sallan SE, Gelber R, Lucas VS, Laszlo J. Antiemetic effect of intramuscular levonantradol in patients receiving anticancer chemotherapy. J Clin Pharmacol 1981; 21(8/9 Suppl): 43S-50S.
64. Jain AK, Ryan JR, McMahon FG, Smith G. Evaluation of intramuscular levonantradol and placebo in acute postoperative pain. J Clin Pharmacol 1981; 21(8/9 Suppl): 320S-326S.
65. Laszlo J, Lucas VS, Jr., Hanson DC, Cronin CM, Sallan SE. Levonantradol for chemotherapy-induced emesis: phase I-II oral administration. J Clin Pharmacol 1981; 21(8/9 Suppl): 51S-56S.
66. EAPCCT. Proceedings of the International Congress of the European Association of Poisons Centres and Clinical Toxicologists. Clin Toxicol 2011; 49 197-269.
67. Fernandez MC, Roth B, Villarreal CL. Fake Marijuana Causing Real Problems in Texas. Clin Toxicol 2011; 49(3): 205.
68. Lonati D, Giampret IA, Petrolin IV, et al. Clinical Identification and Analytical Confirmation of New Synthetic Cannabinoids Poisonings in Italy: Role of the Pavia Poison Centre in the National Early Warning System for Drugs of Abuse. Clinical Toxicology 2011; 49(3): 199.
69. Lapoint J, Le V, Lackey F, et al. Seizures Following Ingestion of the Synthetic Cannabinoid JWH-018. Clin Toxicol 2011; 49(3): 213-214.
70. Westerbergh J, Hulten P. Novel Synthetic Cannabinoids, CRA13, JWH-015, JWH-081 and JWH-210 - Detected in a Case Series. Clin Toxicol 2011; 49(3): 222.
71. Croche Santander B, Alonso Salas MT, Loscertales Abril M. Accidental cannabis poisoning in children: report of four cases in a tertiary care center from southern Spain. Arch Argent Pediatr 2011; 109(1): 4-7.
72. Amirav I, Luder A, Viner Y, Finkel M. Decriminalization of cannabis--potential risks for children? Acta Paediatr 2011; 100(4): 618-619.
73. Spadari M, Glaizal M, Tichadou L, et al. Accidental cannabis poisoning in children: experience of the Marseille poison center. Presse Med 2009; 38(11): 1563-1567.
74. Macnab A, Anderson E, Susak L. Ingestion of cannabis: a cause of coma in children. Pediatr Emerg Care 1989; 5(4): 238-239.
75. Leeson VC, Harrison I, Ron MA, Barnes TR, Joyce EM. The effect of cannabis use and cognitive reserve on age at onset and psychosis outcomes in first-episode schizophrenia. Schizophr Bull 2011.
76. de Hert M, Wampers M, Jendricko T, et al. Effects of cannabis use on age at onset in schizophrenia and bipolar disorder. Schizophr Res 2011; 126(1/3): 270-276.
77. Casadio P, Fernandes C, Murray RM, di Forti M. Cannabis use in young people: The risk for schizophrenia. Neurosci Biobehav Rev 2011; 35(8): 1779-1787.
78. Peters BD, de Haan L, Vlieger EJ, Majoie CB, den Heeten GJ, Linszen DH. Recent-onset schizophrenia and adolescent cannabis use: MRI evidence for structural hyperconnectivity? Psychopharmacol Bull 2009; 42(2): 75-88.
79. Fernandez-Espejo E, Viveros MP, Nunez L, Ellenbroek BA, Rodriguez de Fonseca F. Role of cannabis and endocannabinoids in the genesis of schizophrenia. Psychopharmacology (Berl) 2009; 206(4): 531-549.
80. Croche SB. Accidental cannabis poisoning in children: report of four cases in a tertiary care center from southern Spain. Arch Argent Pediatr 2011; 109(1): 3.
81. James A, Hough M, James S, et al. Greater white and grey matter changes associated with early cannabis use in adolescent-onset schizophrenia (AOS). Schizophr Res 2011; 128(1/3): 91-97.
82. Bossong MG, Niesink RJ. Adolescent brain maturation, the endogenous cannabinoid system and the neurobiology of cannabisinduced schizophrenia. Prog Neurobiol 2010; 92(3): 370-385.
83. Simmons JR, Skinner CG, Williams J, Kang CS, Schwartz MD, Wills BK. Intoxication from smoking spice. Ann Emerg Med 2011; 57(2): 187-188.
84. Simmons J, Cookman L, Kang C, Skinner C. Three cases of spice exposure. Clin Toxicol (Phila) 2011; 49(5): 431-433.
85. Schneir AB, Baumbacher T. Convulsions Associated with the Use of a Synthetic Cannabinoid Product. J Med Toxicol 2011.
86. Olney JW, Collins RC, Sloviter RS. Excitotoxic mechanisms of epileptic brain damage. Adv Neurol 1986; 44: 857-877.
87. Vranyac-Tramoundanas A, Harrison JC, Sawant PM, Kerr DS, Sammut IA. Ischemic cardiomyopathy following seizure induction by domoic Acid. Am J Pathol 2011; 179(1): 141-154.
88. Moore TH, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007; 370(9584): 319-328.
89. Every-Palmer S. Warning: legal synthetic cannabinoid-receptor agonists such as JWH-018 may precipitate psychosis in vulnerable individuals. Addiction 2010; 105(10): 1859-1860.
90. Hurst D, Loeffler G, McLay R. Psychosis associated with synthetic cannabinoid agonists: a case series. Am J Psychiatry 2011; 168(10): 1119.
91. Muller H, Sperling W, Kohrmann M, Huttner HB, Kornhuber J, Maler JM. The synthetic cannabinoid Spice as a trigger for an acute exacerbation of cannabis induced recurrent psychotic episodes. Schizophr Res 2010; 118(1/3): 309-310.
92. Pierre JM. Cannabis, synthetic cannabinoids, and psychosis risk: What the evidence says. Curr Psychiatry 2011; 10(9): 7.
93. Rodgman C, Kinzie E, Leimbach E. Bad Mojo: use of the new marijuana substitute leads to more and more ED visits for acute psychosis. Am J Emerg Med 2011; 29(2): 232.
94. Every-Palmer S. Synthetic cannabinoid JWH-018 and psychosis: an explorative study. Drug Alcohol Depend 2011; 117(21316162): 152-157.
95. Caspi A, Moffitt TE, Cannon M, McClay J, Murray R, Harrington H, et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol- O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry 2005; 57(10): 1117-1127.
96. Benford DM, Caplan JP. Psychiatric sequelae of Spice, K2, and synthetic cannabinoid receptor agonists. Psychosomatics 2011;52(3): 295.
97. Muller H, Huttner HB, Kohrmann M, Wielopolski JE, Kornhuber J, Sperling W. Panic attack after spice abuse in a patient with ADHD. Pharmacopsychiatry 2010; 43(4): 152-153.
98. van der Veer N, Friday J. Persistent psychosis following the use of Spice. Schizophr Res 2011; 130(1/3): 285-286.
99. Zimmermann US, Winkelmann PR, Pilhatsch M, Nees JA, Spanagel R, Schulz K. Withdrawal phenomena and dependence syndrome after the consumption of spice gold. Dtsch Arztebl Int 2009; 106(27): 464-467.
100. Schneir AB, Cullen J, Ly BT. Spice girls: synthetic cannabinoid intoxication. J Emerg Med 2011; 40(3): 296-299.
101. Mir A, Obafemi A, Young A, Kane C. Myocardial infarction associated with use of the synthetic cannabinoid K2. Pediatrics 2011; 128(6): e1622-e1627.
102. Budney AJ, Vandrey RG, Hughes JR, Moore BA, Bahrenburg B. Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms. Drug Alcohol Depend 2007; 86(1): 22-29.
103. Budney AJ, Hughes JR. The cannabis withdrawal syndrome. Curr Opin Psychiatry 2006; 19(3): 233-238.
104. Budney AJ, Hughes JR, Moore BA, Vandrey R. Review of the validity and significance of cannabis withdrawal syndrome. Am J Psychiatry 2004; 161(11): 1967-1977.
105. Vandrey R, Dunn KE, Fry JA, Girling ER. A survey study to characterize use of Spice products (synthetic cannabinoids). Drug Alcohol Depend 2012; 120(1/3): 238-241.
106. Hammersley R. Dangers of banning spice and the synthetic cannabinoid agonists. Addiction 2010; 105(2): 373.
107. McLachlan G. Taking the spice out of legal smoking mixtures. Lancet 2009; 374(9690): 600.
108. Chimalakonda KC, Bratton SM, Le VH, et al. Conjugation of synthetic cannabinoids JWH-018 and JWH-073, metabolites by human UDP-glucuronosyltransferases. Drug Metab Dispos 2011; 39(10): 1967-1976.
109. Coulter C, Garnier M, Moore C. Synthetic cannabinoids in oral fluid. J Anal Toxicol 2011; 35(7): 424-430.
110. ElSohly MA, Gul W, Elsohly KM, Murphy TP, Madgula VL, Khan SI. Liquid chromatography-tandem mass spectrometry analysis of urine specimens for K2 (JWH-018) metabolites. J Anal Toxicol 2011; 35(7): 487-495.
111. Moller I, Wintermeyer A, Bender K, et al. Screening for the synthetic cannabinoid JWH-018 and its major metabolites in human doping controls. Drug Test Anal 2011; 3(9): 609-620.
112. Moore C, Coulter C, Uges D, Tuyay J, van der Linde S, van Leeuwen A, et al. Cannabinoids in oral fluid following passive exposure to marijuana smoke. Forensic Sci Int 2011; 212(1/3): 227-230.
113. Moran CL, Le VH, Chimalakonda KC, et al. Quantitative measurement of JWH-018 and JWH-073 metabolites excreted in human urine. Anal Chem 2011; 83(11): 4228-4236.
114. Uchiyama N, Kikura-Hanajiri R, Shoda T, Fukuhara K, Goda Y. [Isomeric analysis of synthetic cannabinoids detected as designer drugs]. Yakugaku Zasshi 2011; 131(7): 1141-1147.
115. Wintermeyer A, Moller I, Thevis M, et al. In vitro phase I metabolism of the synthetic cannabimimetic JWH-018. Anal Bioanal Chem 2010; 398(5): 2141-2153.
116. Griffiths P, Sedefov R, Gallegos A, Lopez D. How globalization and market innovation challenge how we think about and respond to drug use: 'Spice' a case study. Addiction 2010; 105(6): 951-953.